S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)

Dermata Therapeutics (DRMA) Stock Forecast & Price Target

$0.64
+0.01 (+0.85%)
(As of 11:00 AM ET)
Compare
Today's Range
$0.61
$0.64
50-Day Range
$0.58
$1.12
52-Week Range
$0.56
$10.72
Volume
9,120 shs
Average Volume
998,028 shs
Market Capitalization
$2.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Dermata Therapeutics Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$4.00
525.98% Upside
High Forecast$4.00
Average Forecast$4.00
Low Forecast$4.00
TypeCurrent Forecast
11/28/22 to 11/28/23
1 Month Ago
10/29/22 to 10/29/23
3 Months Ago
8/30/22 to 8/30/23
1 Year Ago
11/28/21 to 11/28/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.00$4.00$4.00$64.00
Predicted Upside525.98% Upside198.51% Upside198.51% Upside212.50% Upside
Get Dermata Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.


DRMA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DRMA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dermata Therapeutics Stock vs. The Competition

TypeDermata TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside525.98% Upside965.31% Upside2,838.02% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/23/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$16.00 ➝ $4.00+198.51%
(Data available from 11/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












DRMA Price Target - Frequently Asked Questions

What is Dermata Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Dermata Therapeutics stock is Buy based on the current 1 buy rating for DRMA. The average twelve-month price prediction for Dermata Therapeutics is $4.00 with a high price target of $4.00 and a low price target of $4.00. Learn more on DRMA's analyst rating history.

Do Wall Street analysts like Dermata Therapeutics more than its competitors?

Analysts like Dermata Therapeutics more than other Medical companies. The consensus rating for Dermata Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how DRMA compares to other companies.

Does Dermata Therapeutics's stock price have much upside?

According to analysts, Dermata Therapeutics's stock has a predicted upside of 198.51% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:DRMA) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -